Clinical trials: Delayed Graft Function
Delayed Graft Function
Study to Improve Renal Function After Kidney Transplantation
The objective of the study is to evaluate the safety and activity of a investigational drug in improving renal function in patients who have undergone renal transplantation and have signs and symptoms of significant renal injury…
- Trial name
- NCT01286727
- Testing
- BB3
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Angion Biomedica Corp
Delayed Function of Renal Transplant
Efficacy and Safety of SANGUINATE™ for Reduction of Delayed Graft Function in Patients Receiving a Kidney Transplant
Safety and efficacy study of SANGUINATE on reduction of delayed graft function (DGF) in patients who will be recipients of a donation after brain death (DBD) donor kidney.
- Trial name
- NCT02490202
- Testing
- SANGUINATE, Normal Saline
- Where
- 20 sites in United States
- Volunteers
- 60 people
- Sponsor
- Prolong Pharmaceuticals
Ischemia Reperfusion Injury
YSPSL for Prevention of Ischemic Reperfusion Injury in Patients Undergoing Cadaveric Orthotopic Liver Transplantation
The study is designed to assess the feasibility of evaluating YSPSL for the amelioration of ischemia reperfusion injury following liver transplantation by administering YSPSL into the liver graft directly ex vivo via the portal…
- Trial name
- YSPSL (NCT00876902)
- Testing
- recombinant P-selectin glycoprotein ligand Ig fusion protein, Viaspan® and saline
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Y's Therapeutics, Inc.
Delayed Graft Function
QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant
The purpose of this trial is to evaluate the reduction in incidence and severity of delayed graft function with kidney allografts from donors >45 years after brain death (DBD).
- Trial name
- ReGIFT (NCT02610296)
- Testing
- QPI-1002
- Where
- 84 sites in United States, Argentina and 9 more
- Volunteers
- 594 people
- Sponsor
- Quark Pharmaceuticals
Renal Transplantation
Efficacy and Safety of Early Versus Delayed Administration of Everolimus in de Novo Renal Transplant Patients
The purpose of this study is to evaluate if the delayed administration of everolimus could reduce the everolimus associated "anti-proliferative complications" (e.g.
- Trial name
- NCT00154297
- Testing
- Everolimus (RAD001)
- Where
- Switzerland
- Volunteers
- 139 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Transplantation
Ex Vivo Normothermic Perfusion in Kidney Transplantation.
A multicenter, prospective and open-label clinical investigation to evaluate the viability, performance and safety of ex vivo normothermic perfusion in kidney transplantation from DCD and DBD donors.
- Trial name
- KidneyARK (NCT05175885)
- Testing
- Ex vivo normothermic perfusion, Cold preservation
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Ebers Medical Technology, S.L.
Kidney Diseases
YSPSL for Prevention of Delayed Graft Function Part B
Selectins have been implicated in the pathogenesis of ischemia/reperfusion (I/R)-induced kidney injury and resultant delayed graft function (DGF). PSGL-1 is a ligand for P-, E-, and L-selectin.
- Trial name
- NCT00298168
- Testing
- YSPSL
- Where
- 15 sites in United States
- Volunteers
- 60 people
- Sponsor
- Y's Therapeutics, Inc.
Kidney Transplantation (Status Post)
Efficacy, Safety, Tolerability and Pharmacokinetic (PK) Study of GSK1070806 for the Prevention of Delayed Graft Function (DGF) in Adult Subjects After Renal Transplantation
This is a phase 2 study to evaluate the efficacy, safety, tolerability and pharmacokinetics of GSK1070806 in subjects undergoing renal transplantation.
- Trial name
- NCT02723786
- Testing
- GSK1070806, 1) basiliximab 2) mycophenolate mofetil (MMF) OR azathioprine 3) tacrolimus 4) corticosteroids
- Where
- 4 sites in Spain, United Kingdom
- Volunteers
- 7 people
- Sponsor
- GlaxoSmithKline
Delayed Graft Function
Renaparin® in Kidney Transplantation
This study evaluates the safety and tolerability of Renaparin in adult patients receiving a deceased donor kidney treated ex-vivo with Renaparin prior to transplantation.
- Trial name
- NCT03773211
- Testing
- Renaparin
- Where
- 3 sites in Sweden
- Volunteers
- 16 people
- Sponsor
- Corline Biomedical AB
Delayed Graft Function
ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function
The main purpose of this study is to evaluate the safety, efficacy and tolerability of ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function.
- Trial name
- VARVARA (NCT05907096)
- Testing
- ARGX-117
- Where
- 45 sites in United States, Australia and 9 more
- Volunteers
- 103 people
- Sponsor
- argenx
Delayed Graft Function
Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)
The purpose of this study was to determine if eculizumab is safe and could be used to prevent delayed graft function (DGF) following kidney transplantation.
- Trial name
- NCT02145182
- Testing
- Eculizumab
- Where
- 78 sites in United States, Australia and 7 more
- Volunteers
- 288 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Liver Diseases
YSPSL for Prevention of Delayed Graft Function in Cadaveric Liver Transplantation
The study is designed to assess the feasibility of evaluating YSPSL for the amelioration of ischemia reperfusion injury following liver transplantation by administering YSPSL into the liver graft directly ex vivo via the portal…
- Trial name
- NCT00450398
- Testing
- YSPSL
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Y's Therapeutics, Inc.
Ischemia-Reperfusion Injury, Kidney Diseases
Reparixin in Prevention of Delayed Graft Function After Kidney Transplantation
The chemokine CXCL8 plays a key role in the recruitment and activation of polymorphonuclear neutrophils in post-ischemia reperfusion injury after solid organ transplantation. Reparixin is a novel, specific inhibitor of CXCL8.
- Trial name
- NCT00248040
- Testing
- Reparixin continuous infusion, reparixin intermittent infusion
- Where
- 9 sites in United States, France and 2 more
- Volunteers
- 80 people
- Sponsor
- Dompé Farmaceutici S.p.A
Delayed Graft Function
Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney
The major objective is to demonstrate the safety and efficacy of ANG-3777 in improving graft function and reducing the severity of delayed graft function (DGF) in recipients at high risk of DGF after receiving a deceased donor…
- Trial name
- NCT02474667
- Testing
- ANG-3777
- Where
- 30 sites in United States
- Volunteers
- 253 people
- Sponsor
- Angion Biomedica Corp
Delayed Graft Function, DGF
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are at high risk of DGF after…
- Conditions
- Delayed Graft Function, DGF, Kidney Transplant
- Trial name
- AWAKE (NCT06830798)
- Testing
- Ravulizumab
- Where
- 130 sites in United States, Argentina and 16 more
- Volunteers
- 450 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Delayed Graft Function
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
When a patient receives a kidney transplant particularly if the kidney is from an older donor or one who has had the kidney removed after their heart has stopped, there is a risk that the newly transplanted kidney may not…
- Trial name
- NCT01794663
- Testing
- OPN-305
- Where
- 50 sites in United States, Austria and 9 more
- Volunteers
- 252 people
- Sponsor
- Opsona Therapeutics Ltd.
Renal Transplantation
Study to Evaluate the Combination of Enteric-coated Mycophenolate Sodium (EC-MPS), Basiliximab, and C2-monitored Cyclosporine in de Novo Renal Transplant Recipients at Potential High Risk of Delayed Graft Function (DGF)
The aim of the study is to assess the short-term benefit of the combination of basiliximab, EC-MPS and cyclosporine microemulsion with C2 monitoring on the prophylaxis of acute rejection in a population of de novo renal…
- Trial name
- NCT00154232
- Testing
- Enteric-Coated Mycophenolate Sodium (EC-MPS)
- Volunteers
- 46 people
- Sponsor
- Novartis Pharmaceuticals
Cadaveric Donor Renal Transplantation, Acute Renal Allograft Rejection
An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.
A multicenter clinical study comparing event-free survival at 6 months after transplant between Thymoglobulin-treated and Simulect-treated adult kidney transplant patients.
- Conditions
- Cadaveric Donor Renal Transplantation, Acute Renal Allograft Rejection, Induction Therapy
- Trial name
- NCT00235300
- Testing
- Thymoglobulin [Anti-thymocyte Globulin (rabbit)], Simulect (basliximab)
- Where
- 28 sites in United States, France and 3 more
- Volunteers
- 240 people
- Sponsor
- Genzyme, a Sanofi Company
Delayed Graft Function, Other Complication of Kidney Transplant
I5NP for Prophylaxis of Delayed Graft Function in Kidney Transplantation
The purpose of this study is to determine whether a single administration of QPI-1002 (also known as I5NP) can prevent DGF in patients undergoing deceased donor kidney transplantation.
- Trial name
- NCT00802347
- Testing
- I5NP, Saline
- Where
- 50 sites in United States, Canada and 3 more
- Volunteers
- 374 people
- Sponsor
- Quark Pharmaceuticals
Delayed Graft Function, Other Complications of Kidney Transplant
Biomarkers of Aging as Predictors of Kidney Transplant Function
The primary purpose of this study is to measure the correlation between baseline expression of aging biomarkers, SenesceTest in blood of organ donor and renal graft function.
- Trial name
- NCT02335333
- Testing
- No treatment
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Sapere Bio